drugset

drugset / Trial / NCT02096315

Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.

NCT02096315 ↗

Phase 2 Terminated 20 enrolled Polyphor Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa infection.

Timeline

Start: 2013-12
Primary completion: 2015-11
Completion: 2015-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Murepavadin	Peptide	—	Intravenous

Indications